Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 800 participants.

Also called NCT02831205

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 800 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02831205
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02831205. Randomized; no masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2017-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
Acronym
ABSORB-LONG
Condition
Percutaneous Transluminal Coronary Angioplasty
Intervention (Device)
everolimus-eluting bioresorbable vascular (Absorb) scaffold
Intervention (Device)
everolimus-eluting cobalt-chromium (Xience) stent
Lead sponsor
Duk-Woo Park, MD (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)

Record details

Record id
cardio:ct-nct02831205
Content hash
d0027144fb1e75534faeb489392bd0bdb6f2dacf9c17fb4d166e2aa001982472